Trazodone FDA Approval History

What Is Trazodone and Why Does Its Regulatory History Matter?

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) approved for major depressive disorder. It blocks serotonin 5-HT2A receptors while also inhibiting the serotonin transporter (SERT), a dual mechanism that separates it from pure SSRIs. Understanding the regulatory record matters for prescribers, patients, and telehealth clinicians because label changes over four decades reflect real post-market safety discoveries, not just bureaucratic paperwork.

The Drug's Basic Pharmacology

Trazodone's sedative profile comes primarily from histamine H1 and alpha-1 adrenergic receptor antagonism at low doses (25 to 100 mg). At antidepressant doses (150 to 400 mg/day), the serotonergic effects dominate. This dose-dependent pharmacology is one reason the drug is so commonly prescribed off-label for insomnia at sub-antidepressant doses, a practice that is widespread despite not appearing in the approved indication.

Why Regulatory History Is Clinically Relevant

Post-market label changes to trazodone have affected prescribing across three areas: pediatric and young-adult populations (black-box suicidality warning), cardiac safety (QT prolongation updates), and sexual adverse effects (priapism labeling). Each of these changes followed specific data, and the timelines are traceable through the FDA's Drugs@FDA database.

Original FDA Approval: December 1981

Trazodone was approved by the FDA in December 1981 under New Drug Application (NDA) 018207, with Mead Johnson Pharmaceuticals holding the original New Drug Approval. The approved indication was treatment of depression, which in modern terminology maps to major depressive disorder (MDD) in adults.

Pre-Approval Clinical Program

The original approval was based on a controlled clinical trial package submitted to the FDA demonstrating efficacy versus placebo in outpatient depression. At the time of approval, the standard comparator class was tricyclic antidepressants (TCAs). Trazodone's differentiated safety profile, specifically a lower risk of anticholinergic toxicity and reduced lethality in overdose relative to TCAs such as amitriptyline, was among the features noted in the original regulatory review.

Original Labeled Dose Range

The initial labeling established a starting dose of 150 mg/day in divided doses for outpatients, with titration in increments of 50 mg every three to four days. The labeled maximum dose was 400 mg/day for outpatients and 600 mg/day for inpatients with severe depression. Those dose ceilings remain in the current prescribing information.

The Brand Name "Desyrel"

Mead Johnson marketed trazodone as Desyrel. The brand was later acquired by Apothecon, and brand-name Desyrel was eventually discontinued in the United States following generic entry. As of 2025, trazodone is dispensed almost exclusively as generic trazodone hydrochloride tablets in 50 mg, 100 mg, 150 mg, and 300 mg strengths.

Generic Entry and ANDA Approvals

The first generic trazodone ANDAs received FDA approval in 1986, approximately five years after the brand's NDA. Generic manufacturers demonstrated bioequivalence to Desyrel under standard 80 to 125% confidence interval criteria for AUC and Cmax.

Current Generic Field

Trazodone is now one of the most widely manufactured generic antidepressants in the United States. The FDA's Orange Book lists dozens of approved ANDA holders for trazodone hydrochloride tablets across the 50 mg, 100 mg, 150 mg, and 300 mg strengths. The FDA's current reference listed drug (RLD) for the immediate-release formulation is Desyrel, even though no brand-name product is actively marketed.

Market Penetration

Generic penetration for trazodone exceeds 99% of dispensed prescriptions. According to IQVIA data analyzed through 2022, trazodone ranks among the top 25 most prescribed medications in the United States across all therapeutic categories, with approximately 24 million prescriptions dispensed annually. Its off-label use for insomnia drives a substantial share of that volume.

Extended-Release Formulation: Oleptro (NDA 022411)

The FDA approved an extended-release trazodone tablet under the brand name Oleptro on March 2, 2010 (NDA 022411). Labopharm developed the formulation using its CONTRAMID drug-delivery technology, which produced a flatter pharmacokinetic profile compared to immediate-release trazodone.

Regulatory Basis for Oleptro

The Oleptro NDA included two key phase 3 trials. The key study enrolled 412 adults with MDD and demonstrated a statistically significant improvement in HAMD-17 total score versus placebo at week 8 (P<0.001). The once-daily formulation was labeled at a starting dose of 150 mg/day, with titration to a maximum of 375 mg/day.

Discontinuation From U.S. Market

Despite FDA approval, Oleptro was withdrawn from the U.S. Market by Labopharm in 2014 for commercial rather than safety reasons. The FDA's Orange Book lists Oleptro as a discontinued reference listed drug. Generic extended-release trazodone has not entered the U.S. Market at scale as of early 2025.

Black-Box Suicidality Warning: 2004 and 2007

The most clinically significant regulatory action in trazodone's post-approval history is the addition of a black-box warning for suicidality. This warning was added in 2004 following an FDA review of pediatric antidepressant trial data and was expanded in 2007 to include young adults.

The 2004 FDA Pediatric Suicidality Action

In October 2004, the FDA issued a Public Health Advisory and required a class-wide black-box warning for all antidepressants regarding an increased risk of suicidal thinking and behavior in pediatric patients (under age 18). The action was based on a meta-analysis of 24 placebo-controlled trials involving approximately 4,400 pediatric patients across nine antidepressant drugs. The pooled analysis found a 4% rate of suicidal ideation or behavior in drug-treated patients versus 2% in placebo-treated patients, a doubling in relative risk.

Trazodone was included in this class-wide action even though it was not one of the nine drugs in the primary meta-analysis, because the FDA extended the warning to all antidepressants approved for any indication.

The 2007 Expansion to Young Adults

In May 2007, the FDA expanded the black-box warning to include young adults aged 18 to 24 years, based on additional pooled trial data. A re-analysis of 295 trials covering approximately 77,000 patients showed an elevated risk of suicidal behavior in patients under 25 years old. The current trazodone prescribing information states that "antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies" and instructs prescribers to balance this risk against clinical need. Trazodone is not approved for use in pediatric patients.

What the Current Label Actually Says

The 2007 FDA requirement produced a uniform Medication Guide that all antidepressant manufacturers, including trazodone generic makers, must distribute with each dispensed prescription. The Medication Guide instructs patients and caregivers to watch for worsening depression, suicidal thoughts, unusual changes in behavior, anxiety, agitation, panic attacks, insomnia, irritability, aggression, restlessness, mania, and other unusual changes in behavior, particularly in the first one to two months of treatment or after dose changes.

Cardiac Safety: QTc Prolongation

Trazodone carries a risk of QTc interval prolongation, a fact reflected in post-market label updates. The mechanism is blockade of cardiac hERG potassium channels (IKr), which delays ventricular repolarization.

Post-Market QT Data

A 2005 review by Mendelson in the Journal of Clinical Psychiatry examined trazodone's cardiovascular profile, noting that QT prolongation had been observed in case reports and small pharmacodynamic studies, particularly at supratherapeutic doses or when combined with other QT-prolonging agents [1]. The current FDA label includes a precaution advising that trazodone should be used with caution in patients with known QT prolongation, those taking other QT-prolonging drugs, or those with bradycardia, hypokalemia, or hypomagnesemia.

Clinical Implications for Telehealth Prescribers

At doses used for insomnia (25 to 100 mg), the QTc prolongation risk is low in otherwise healthy adults. At antidepressant doses (150 to 400 mg/day), a baseline ECG should be considered in patients with cardiac risk factors. The CredibleMeds QTc database (maintained by the Arizona CERT and endorsed by the FDA's Sentinel program) lists trazodone as a drug with "conditional risk" for QT prolongation, meaning the risk is dose- and interaction-dependent.

Priapism: A Rare but Serious Post-Market Safety Signal

The trazodone label includes a specific warning for priapism, a prolonged erection lasting more than four hours that can result in permanent erectile dysfunction if untreated. This signal emerged in the early post-marketing period.

Incidence Estimate

The FDA label estimates a priapism incidence of approximately 1 in 6,000 male patients exposed to trazodone. This figure comes from early post-market spontaneous adverse event reports compiled in the 1980s. The actual incidence may differ given underreporting in spontaneous surveillance systems, but the 1-in-6,000 estimate has been the labeled figure for decades.

Mechanism and Risk Factors

Priapism appears to result from trazodone's alpha-1 adrenergic receptor antagonism in penile erectile tissue, impairing the vasoconstriction required for detumescence. Risk may be higher in patients with sickle cell anemia, leukemia, or other conditions predisposing to priapism, and in those taking other alpha-1 blockers (e.g., tamsulosin for benign prostatic hyperplasia). Prescribers should counsel male patients to seek immediate emergency care for an erection lasting more than two to three hours.

Current Label Language on Priapism

The FDA-approved prescribing information states: "Trazodone should be used with caution in men with conditions that might predispose them to priapism (e.g., sickle cell anemia, multiple myeloma, or leukemia), and patients should be advised to seek immediate medical assistance if they develop a prolonged erection."

Serotonin Syndrome Warning

Post-market case reports led to the addition of a serotonin syndrome warning in trazodone's prescribing information, consistent with the serotonergic mechanism.

Interaction With MAOIs

The trazodone label carries a contraindication for concurrent use with monoamine oxidase inhibitors (MAOIs). The label specifies a washout of at least 14 days after stopping an MAOI before starting trazodone, and at least 14 days after stopping trazodone before starting an MAOI. This is the same 14-day bidirectional washout required for SSRIs and SNRIs.

Risk With Other Serotonergic Agents

The current label warns of serotonin syndrome risk when trazodone is combined with other serotonergic drugs, including SSRIs, SNRIs, triptans, linezolid, fentanyl, lithium, tramadol, and St. John's Wort. The FDA's 2006 Public Health Advisory on serotonin syndrome explicitly named trazodone as a drug that can precipitate serotonin syndrome in combination with triptans, even though trazodone is not a triptan-augmenting antidepressant in common practice.

FDA Drug Safety Communications and Sentinel Surveillance

Since trazodone's approval, the FDA's evolving post-market surveillance infrastructure has monitored the drug through multiple reporting systems.

MedWatch and FAERS

The FDA Adverse Event Reporting System (FAERS) contains post-market case reports for trazodone across multiple safety domains including QT prolongation, serotonin syndrome, priapism, hypotension, and falls in elderly patients. FAERS data are publicly queryable through the FDA's openFDA API.

FDA Sentinel System

The FDA Sentinel System, a distributed database covering more than 300 million patients' electronic health records and claims data, has been used for active surveillance of antidepressants including trazodone since Sentinel's launch in 2009. Sentinel enables the FDA to conduct rapid epidemiologic studies far beyond what spontaneous reporting alone can support.

Medication Error and Drug Interaction Signals

The FDA has received reports of medication errors involving trazodone and tramadol due to name confusion, and reports of drug interactions with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) that substantially increase trazodone plasma concentrations. The current label addresses CYP3A4 interactions, recommending dose reduction when strong CYP3A4 inhibitors are co-administered. CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin) may reduce trazodone plasma levels by 50% or more.

Off-Label Use for Insomnia: Regulatory Perspective

Trazodone is the most commonly prescribed non-benzodiazepine, non-Z-drug sleep agent in the United States, yet this indication has never received FDA approval. This regulatory gap has clinical and medico-legal implications.

Scale of Off-Label Prescribing

Surveys of physician prescribing patterns have consistently found that 50 to 70% of trazodone prescriptions are written for insomnia rather than depression. A cross-sectional analysis of U.S. Ambulatory care visits estimated that trazodone was the most frequently prescribed medication for sleep-onset and sleep-maintenance insomnia by primary care physicians, ahead of zolpidem in some practice settings.

FDA's Position on Off-Label Use

The FDA does not regulate the practice of medicine. Clinicians may legally prescribe approved drugs for unapproved uses based on their clinical judgment. The FDA has not issued specific guidance restricting trazodone's off-label use for insomnia, nor has it required manufacturers to study this indication under a formal post-marketing commitment.

What the Evidence Shows

The most often-cited controlled data on trazodone for insomnia come from studies in patients with comorbid depression or alcohol use disorder. A 2005 review by Mendelson in the Journal of Clinical Psychiatry concluded that trazodone at doses of 50 to 150 mg reduced sleep latency and improved sleep continuity in these populations, though evidence in primary insomnia (without psychiatric comorbidity) was limited at the time [1]. The 2017 American Academy of Sleep Medicine (AASM) Clinical Practice Guideline for chronic insomnia treatment gave trazodone a "weak" recommendation against use as a first-line agent, citing insufficient evidence from randomized controlled trials in primary insomnia populations.

Current FDA-Approved Prescribing Information: Key Label Sections

The most recent trazodone prescribing information, accessible via Drugs@FDA (NDA 018207) and the FDA's DailyMed database, contains the following key sections relevant to clinical practice.

Contraindications

The label lists one absolute contraindication: concurrent use with MAOIs or use within 14 days of MAOI discontinuation. No other absolute contraindications are listed, making trazodone's contraindication profile notably narrower than TCAs.

Warnings and Precautions

Beyond the black-box suicidality warning and the priapism warning, the label includes precautions for:

• Hypotension and syncope (alpha-1 antagonism)
• Abnormal bleeding (serotonin-mediated platelet dysfunction, particularly with NSAIDs or anticoagulants)
• Activation of mania or hypomania in patients with undiagnosed bipolar disorder
• Cognitive and motor impairment (sedation at higher doses)
• Discontinuation syndrome (though less pronounced than with SSRIs)

Pregnancy and Lactation

Trazodone is FDA Pregnancy Category C under the older classification system. Under the current Pregnancy and Lactation Labeling Rule (PLLR) framework, the label notes that there are no adequate and well-controlled studies in pregnant women, that animal studies showed teratogenic effects at doses substantially above the human therapeutic dose, and that neonatal exposure in the third trimester has been associated with neonatal adaptation syndrome (respiratory distress, feeding difficulties, hypoglycemia). The label states that trazodone is excreted in human breast milk and advises caution in nursing mothers.

Regulatory Comparison: Trazodone vs. Other Antidepressants

Trazodone's regulatory profile differs from the major SSRI and SNRI classes in several ways worth noting for prescribers.

No Approved Pediatric Indication

SSRIs such as fluoxetine (approved for MDD in children age 8 and older, NDA 018936) and sertraline (approved for OCD in children age 6 and older) carry approved pediatric indications. Trazodone has no approved pediatric indication. The black-box warning for suicidality therefore applies to a population for whom the drug is already off-label if used in patients under 18.

No REMS Requirement

Unlike some newer antidepressants and psychotropic medications, trazodone does not require a Risk Evaluation and Mitigation Strategy (REMS). This reflects the FDA's judgment that the existing label warnings, the Medication Guide, and standard prescriber and patient education are sufficient risk mitigation tools for this drug.

Generic Substitution Policy

State pharmacy substitution laws universally permit generic trazodone substitution for brand-name Desyrel (now discontinued) without prescriber authorization, given that all approved ANDAs have demonstrated bioequivalence. Prescribers who wish to prevent generic substitution must write "dispense as written" (DAW), though no clinical evidence supports that any generic trazodone formulation performs differently from another.

Timeline Summary: Trazodone Regulatory Milestones

The following timeline captures the major regulatory events in trazodone's U.S. History:

• 1981: FDA approves NDA 018207 (Desyrel, Mead Johnson) for major depressive disorder.
• 1986: First generic trazodone ANDAs approved; generic price competition begins.
• Late 1980s: Post-market signals for priapism accumulate; FDA label updated with 1-in-6,000 priapism incidence estimate.
• 2004: FDA requires class-wide black-box warning for pediatric suicidality across all antidepressants, including trazodone.
• 2007: FDA expands suicidality warning to young adults aged 18 to 24.
• 2010: FDA approves Oleptro (NDA 022411), extended-release trazodone 150 mg and 300 mg tablets.
• 2014: Oleptro withdrawn from U.S. Market for commercial reasons; no safety-related withdrawal.
• 2017: AASM Clinical Practice Guideline gives trazodone a weak recommendation against first-line use in chronic insomnia.
• 2025: Immediate-release generic trazodone remains widely available; no active brand-name product marketed in the United States.